Skip to content

Study · Randomized controlled trial · n = 24 · 2013

4 results

Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.

Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M

European journal of neurology12 Nov 2012Cited by 16 (Europe PMC)

PMID23146065 (opens in a new tab)PMCIDPMC4747634 (opens in a new tab)DOI10.1111/ene.12009 (opens in a new tab)PepBankPUB-23146065
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In blepharospasm patients receiving botulinum toxin, acetyl hexapeptide‑8 showed a trend toward longer time to baseline JBRS versus placebo.

    In plain wordsIn blepharospasm patients receiving botulinum toxin, acetyl hexapeptide‑8 tended to extend time to baseline symptom scores versus placebo.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    IncreaseTime to baseline JBRS
    Study

    n = 24

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Locomotor and behavioral activity · Eye
    Studied dose
    Dose not stated · topical dailyAs given in this study (human).

    Measurements

    Time to baseline JBRS
    3.7 months
    active group
    Time to baseline JBRS
    3 months
    placebo

    Source sentences

    Summary
    There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.7 months vs. 3.0 months), and for better scores in the active group.
    3 context sentences
    Summary · context
    Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP.
    Summary · context
    The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8.
    Summary · context
    Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.
  2. 02HumanRandomized controlled trialSafety outcome

    No significant adverse events occurred in the blepharospasm trial of topical acetyl hexapeptide‑8 with botulinum toxin therapy.

    In plain wordsNo significant adverse events occurred in the trial of topical acetyl hexapeptide‑8 with botulinum toxin therapy for blepharospasm.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableSignificant adverse events
    Study

    n = 24

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated · topical dailyAs given in this study (human).

    Source sentences

    Summary
    There were no significant adverse events.
    3 context sentences
    Summary · context
    Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP.
    Summary · context
    The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8.
    Summary · context
    Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In blepharospasm patients receiving botulinum toxin, topical acetyl hexapeptide‑8 showed a trend toward better scores than placebo.

    In plain wordsIn blepharospasm patients receiving botulinum toxin, topical acetyl hexapeptide‑8 tended to improve scores compared with placebo.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Direction not reportedBlepharospasm scores
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Locomotor and behavioral activity · Eye
    Studied dose
    Dose not stated · topical dailyAs given in this study (human).

    Source sentences

    Summary
    There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.7 months vs. 3.0 months), and for better scores in the active group.
    3 context sentences
    Summary · context
    Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP.
    Summary · context
    The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8.
    Summary · context
    Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In the active blepharospasm group, 4/12 patients had considerable extension of symptom control after botulinum toxin, ranging from 3.3-7.1 months.

    In plain wordsIn the acetyl hexapeptide‑8 group, 4/12 blepharospasm patients had extended symptom control after botulinum toxin, ranging from 3.3-7.1 months.

    Peptide
    Argireline (acetyl hexapeptide-8)
    Outcome
    Not applicableConsiderable extension of symptom control
    Study

    n = 12

    Outcome group
    Locomotor and behavioral activity · Eye
    Studied dose
    Dose not stated · topical dailyAs given in this study (human).

    Measurements

    Patients with extension
    4 patients
    active group
    Extension of symptom control
    3.3 to 7.1 months
    active group responders

    Source sentences

    Summary
    One-third (4/12) of the patients in the active group had a considerable extension of symptom control after BoNT (range: 3.3-7.1 months).
    3 context sentences
    Summary · context
    Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP.
    Summary · context
    The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8.
    Summary · context
    Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.